臨床検査53巻10号

2009年10月発行

今月の主題 血栓症と臨床検査 各論 〈抗血栓療法のモニター〉

血栓溶解療法のモニター

著者： 上嶋繁¹² 松尾理²

所属機関： ¹近畿大学農学部食品栄養学科 ²近畿大学医学部第2生理学教室

ページ範囲：P.1181 - P.1185

　急性心筋梗塞や脳梗塞などの血栓性疾患に対して血栓溶解療法が実施されるようになり，多くの治療効果が望まれるようになった．血栓溶解療法は血液線溶系を基に考え出され，線溶系を亢進させて血栓を溶解する治療法である．そこで，血栓溶解療法のモニターとして，血栓溶解を反映する検査とともに線溶系の亢進，すなわち出血傾向を反映する検査も必要である．さらに，心エコーや神経症状の観察など，それぞれの血栓性疾患に応じたモニターも重要である．

参考文献

1) Rijken DC, Lijnen HR：New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost　7：4-13, 2009

2) Sprengers ED, Kluft C：Plasminogen activator inhibitors. Blood　69：381-387, 1987

3) Moroi M, Aoki N：Isolation and characterization of α2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem　251：5956-5965, 1976

4) Wiman B, Collen D：Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem　78：19-26, 1997

5) Ueshima S, Matsuo O：Development of new fibrinolytic agents. Curr Pharm Des　12：849-857, 2006

6) 松尾理，小杉忠誠，美原恒，他：ウロキナーゼ療法の適応と効果判定．日本医事新報　2867：26-30, 1979

7) Matsuo O, Rijken DC, Collen D：Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature　291：590-591, 1981

8) Kasai S, Arimura H, Nishida M, et al：Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin J Biol Chem　260：12377-12381, 1985

9) Matsuo O, Okada K, Fukao H, et al：Thrombolytic properties of staphylokinase. Blood　76：925-929, 1990

10) Medved L, Weisel JW；Fibrinogen and Factor XIII Subcommittee of Scientific Standardization Committee of International Society on Thrombosis and Haemostasis：Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost　7：355-359, 2009

11) Walker JB, Nesheim ME：The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem　274：5201-5212, 1999

12) Koopman J, Haverkate F, Koppert P, et al：New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody. J Lab Clin Med 1987　109：75-84, 1987

13) Righini M, Perrier A, De Moerloose P, et al：D-Dimer for venous thromboembolism diagnosis：20 years later. J Thromb Haemost　6：1059-1071, 2008

14) Hirsch DR, Goldhaber SZ：Contemporary use of laboratory tests to monitor safety and efficacy of thrombolytic therapy. Chest　101：98S-105S, 1992

15) Soe G, Kohno I, Inuzuka K, et al：A rapid latex immunoassay for the detection of plasmin-alpha 2-plasmin inhibitor complex. Utilization of two monoclonal antibodies differentially recognizing respective components of the complex. Blood Coagul Fibrinolysis　6：249-258, 1995

16) Juhan-Vague I, Allessi M：A manual of Laboratory Technique, Kluwer, Dordrecht, pp134-145, 1992

17) Friberger P：Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems. 8. Method for the assay of plasminogen activator. Scand J Clin Lab Invest　42：55-63, 1982

18) Rånby M, Norrman B, Wallén P：A sensitive assay for tissue plasminogen activator. Thromb Res　27：743-749, 1982

19) Egelund R, Schousboe SL, Sottrup-Jensen L, et al：Type-1 plasminogen-activator inhibitor-conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur J Biochem　248：775-785, 1997

20) Genser N, Lechleitner P, Maier J, et al：Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. Clin Chem　44：209-214, 1998

21) Brott T, Adams HP Jr, Olinger CP, et al：Measurements of acute cerebral infarction：a clinical examination scale. Stroke　20：864-870, 1989

22) 日本脳卒中学会医療向上・社会保険委員会，rt-PA(アルテプラーゼ)静注療法指針部会：rt-PA(アルテプラーゼ)静注療法適正治療指針．脳卒中　27：327-354, 2005